News and Media
News and Media
Onxeo to present new preclinical data highlighting AsiDNA™’s ability to fight tumor resistance and protect from anticancer treatment toxicity at AACR Annual Meeting 2022
March 31, 2022
Onxeo’s new preclinical data confirm the relevance of combining AsiDNA™ with PARP inhibitors in treating homologous recombination proficient tumors
March 9, 2022
Onxeo Announces its Financial Agenda for 2022
January 13, 2022
Onxeo appoints Julien Miara as new interim CEO
January 3, 2022
Onxeo Continues to Strengthen its Board of Directors
November 23, 2021
New preclinical data confirm the ability of AsiDNA™ to tackle the drug-tolerant persister cells and prevent tumor resistance in several combination treatments
August 12, 2021
Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States
December 10, 2020
Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020
December 10, 2020
Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results
November 9, 2020
Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors
October 22, 2020
Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan
October 21, 2020
Publication of the 2020 Half-Yearly Financial Report
September 29, 2020
Onxeo reports its financial results for the first half of 2020 and provides an update on its activities
September 17, 2020
Onxeo to Attend Key Investor Conferences and Events in the Second Half of 2020
September 8, 2020
Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer
August 27, 2020
Press Release Signup
Subscribe to receive our Press Releases when they come out.
